Enrico Mini 
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
HomePage
Bio
Enrico Mini, M.D., Ph.D., is Professor of Medical Oncology and the Director of the Specialty School of Medical Oncology at the University of Florence (UniFI), School of Human Health Sciences. He is Head of the Laboratory of Cancer Pharmacology and Chemotherapy at UniFI, and Director of the Unit of Translational Oncology at the Careggi University-Hospital of Florence.
Dr. Mini received his M.D. in 1977 and his Ph.D. in 1988 from the University of Florence. He received post-graduate training at Yale University School of Medicine (Departments of Pharmacology and Internal Medicine) in the USA. He was later Lecturer in Cellular Pharmacology and in Cancer Pharmacology at the Universities of Siena and Ferrara, respectively. Dr. Mini was appointed Associate Professor of Pharmacology in 1992 at the School of Medicine, UniFI, and grew up through the ranks to become Professor of Pharmacology in 2001 and Professor of Medical Oncology in 2008.
He is a recognized expert in cancer pharmacology and therapeutics, clinical oncology, and translational cancer research. Dr. Mini has a double competence in cancer pharmacology and oncology, allowing him to master the mechanistic aspects of drug action and resistance as well as the discovery and application of pharmacogenomic markers of drug response and toxicity and their translation into clinical trials and medical practice. Dr. Mini acted as the principal investigator and/or coordinator within the framework of several funded research projects. His main research interests comprise molecular mechanisms of tumor drug resistance (in particular to antimetabolites and metal-based drugs), pharmacogenomics and pharmacogenetics of anticancer drugs, and medical treatment of colorectal cancer.
He is the author and co-author of more than 170 peer reviewed original articles and more than 60 reviews, editorials, book chapters, and letters. Dr. Mini’s cumulative Impact Factor is approximately 1000 and his H index is 51 (Google Scholar). His research has contributed to elucidate the mechanisms of methotrexate and fluorouracil action and resistance, the biochemical bases of their drug synergism in experimental models and in cancer patients and to shape optimal administration schedules of these drugs in the clinic.
Dr. Mini has received awards and honors for his research accomplishments. Among them, the Leukemia Society of America Special Fellow Award (New York) in 1982, the Lady Tata Memorial Trust Award (London) and the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award (Milan) in 1988, the International Society of Antimicrobial Chemotherapy Fellow Award in 2019. He served as the Chairman of the Cancer Section of the International Society of Chemotherapy from 2007 to 2013. Currently, he is a member of the Steering Committee of the European Organization for Research and Treatment of Cancer (EORTC), Pan-European Trials in Adjuvant Colon Cancer (PETACC) and he is also Editor of the Journal of Chemotherapy, and Co-Editor of Oncology Research for the European Continent. In 2010 he was a Visiting Professor at Yale. From 2018 he is the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology.
His laboratory is studying various epigenetic strategies to circumvent chemotherapy resistance and novel biomarkers of drug response and toxicity in colorectal cancer. Finally, he has been participant or the principal investigator of several key clinical trials in gastrointestinal cancers.
Dr. Mini received his M.D. in 1977 and his Ph.D. in 1988 from the University of Florence. He received post-graduate training at Yale University School of Medicine (Departments of Pharmacology and Internal Medicine) in the USA. He was later Lecturer in Cellular Pharmacology and in Cancer Pharmacology at the Universities of Siena and Ferrara, respectively. Dr. Mini was appointed Associate Professor of Pharmacology in 1992 at the School of Medicine, UniFI, and grew up through the ranks to become Professor of Pharmacology in 2001 and Professor of Medical Oncology in 2008.
He is a recognized expert in cancer pharmacology and therapeutics, clinical oncology, and translational cancer research. Dr. Mini has a double competence in cancer pharmacology and oncology, allowing him to master the mechanistic aspects of drug action and resistance as well as the discovery and application of pharmacogenomic markers of drug response and toxicity and their translation into clinical trials and medical practice. Dr. Mini acted as the principal investigator and/or coordinator within the framework of several funded research projects. His main research interests comprise molecular mechanisms of tumor drug resistance (in particular to antimetabolites and metal-based drugs), pharmacogenomics and pharmacogenetics of anticancer drugs, and medical treatment of colorectal cancer.
He is the author and co-author of more than 170 peer reviewed original articles and more than 60 reviews, editorials, book chapters, and letters. Dr. Mini’s cumulative Impact Factor is approximately 1000 and his H index is 51 (Google Scholar). His research has contributed to elucidate the mechanisms of methotrexate and fluorouracil action and resistance, the biochemical bases of their drug synergism in experimental models and in cancer patients and to shape optimal administration schedules of these drugs in the clinic.
Dr. Mini has received awards and honors for his research accomplishments. Among them, the Leukemia Society of America Special Fellow Award (New York) in 1982, the Lady Tata Memorial Trust Award (London) and the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award (Milan) in 1988, the International Society of Antimicrobial Chemotherapy Fellow Award in 2019. He served as the Chairman of the Cancer Section of the International Society of Chemotherapy from 2007 to 2013. Currently, he is a member of the Steering Committee of the European Organization for Research and Treatment of Cancer (EORTC), Pan-European Trials in Adjuvant Colon Cancer (PETACC) and he is also Editor of the Journal of Chemotherapy, and Co-Editor of Oncology Research for the European Continent. In 2010 he was a Visiting Professor at Yale. From 2018 he is the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology.
His laboratory is studying various epigenetic strategies to circumvent chemotherapy resistance and novel biomarkers of drug response and toxicity in colorectal cancer. Finally, he has been participant or the principal investigator of several key clinical trials in gastrointestinal cancers.
Research Interests
leukemia, antimetabolites and metal-based drug resistance, gastrointestinal cancers, cancer pharmacogenomics, pharmacogenetics.
Contributions:
Special Issue:
